Organization | Dey

Dey Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4

Founded: Napa CA United States (1977)

Status: Acquired by Mylan (2007)

Organization Overview

First Clinical Trial

2002

NCT00215371

First Marketed Drug

1986

acetylcysteine (mucomyst)

First NDA Approval

1999

poractant alfa (curosurf)

Last Known Activity

2012

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

DEY

Active Ingredients

Marketed Drugs (5)

acetylcysteine (mucomyst) (1986)

isoetharine (bronkosol)

metaproterenol (alupent)

poractant alfa (curosurf) (1999 NDA)

Drugs in Phase 4 Trials (1)

formoterol (foradil) (18 trials)

Drugs in Phase 3 Trials (3)

albuterol (proventil) (1 trial)

ipratropium (atrovent) (1 trial)

tiotropium (spiriva) (1 trial)

Drugs in Phase 2 Trials (2)

fluticasone (cutivate) (6 trials)

salmeterol (serevent) (1 trial)

Drugs in Other Trials (1)

cyclamen europaeum (1 trial)

Indications

Approved Indications

Respiratory Distress Syndrome, Newborn

Experimental Indications (Clinical Trials, Phases 1-4)

Asthma (Phase 2)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 21
# of Trial APIs: 7